However, despite encouraging results achieved with targeted treatments, in association or not with chemotherapy, improvements in overall survival of FLT3-ITD+ AML are still modest, since most patients eventually relapse [8–11]. The gene discussed is FLT3; the disease is acute myeloid leukemia.